What is Infliximab Renflexis?
Infliximab Renflexis is a brand of infliximab, an anti-TNF (tumor necrosis factor) biologic medicine used for several inflammatory autoimmune conditions. It is administered by intravenous (IV) infusion.
What conditions is it used to treat?
Infliximab (including Renflexis) is commonly prescribed for autoimmune inflammatory diseases such as:
- Rheumatoid arthritis
- Crohn’s disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Plaque psoriasis (in eligible patients)
How is Renflexis given?
Renflexis is given as an IV infusion in a clinical setting. The dosing schedule depends on the condition being treated and how the patient responds.
What are common side effects patients ask about?
Because infliximab affects the immune system, common concerns include:
- Infusion-related reactions
- Increased risk of infections
- Potential worsening or reactivation of infections that the body may not notice early (for example, tuberculosis or certain viral infections)
Can Renflexis be switched with other infliximab products?
Renflexis is one of several infliximab brands/versions. In practice, patients may be switched between infliximab products depending on prescribing and pharmacy availability, insurance coverage, and clinical judgment. Any switch is typically handled with attention to monitoring and response.
How does Renflexis relate to patents and biosimilar competition?
If you’re researching exclusivity, pricing, or competitive landscape for infliximab brands and biosimilars, DrugPatentWatch.com tracks related patent activity and can be a useful starting point for the commercial timeline. [1]
Sources:
[1] https://www.drugpatentwatch.com/